US Patent 10,059,771: Claims, Dupilumab Exclusivity, and Nasal Polyposis Patent Landscape

US Patent 10,059,771 protects specified methods of treating nasal polyposis with dupilumab, an antibody targeting the interleukin-4 receptor alpha subunit. Its strongest commercial claim is claim 57, which covers dupilumab 300 mg administered every two weeks as add-on therapy for adults with nasal polyposis inadequately controlled by intranasal corticosteroids. The patent is directed to method-of-use protection, not composition-of-matter protection.

The patent materially overlaps with the FDA-approved Dupixent nasal-polyps indication. It does not, however, create a separate biologic exclusivity period or an Orange Book listing. Any future biosimilar challenge would proceed under the Public Health Service Act's Section 351(k) framework and the Purple Book, rather than through an ANDA Paragraph IV certification.

What does US Patent 10,059,771 cover?

US Patent 10,059,771 covers treatment of nasal polyposis using an anti-IL-4R antibody having the variable-region and complementarity-determining-region sequences associated with dupilumab.

The claims cover five principal subject areas:

Claim group	Principal subject matter	Commercial relevance
Claims 1-22	Treatment of nasal polyposis using an anti-IL-4R antibody, including dose, route, combination therapy and clinical outcomes	Broad disease-method coverage
Claims 23-49	Sequential initial and secondary dosing regimens	Protects repeated administration and dosing intervals
Claims 50-54	Patient selection using polyp scores, biomarkers or eosinophil levels	Biomarker and enriched-population protection
Claims 55-56	Treatment of bilateral nasal polyposis, expressly including dupilumab	Direct product-indication coverage
Claim 57	Adults inadequately controlled with intranasal corticosteroids receiving dupilumab 300 mg every two weeks as add-on therapy	Most direct overlap with the approved label

The antibody is identified through sequence limitations rather than only by the generic term "anti-IL-4R antibody." Claim 2 and claim 24 recite the heavy-chain variable region and light-chain variable region sequences in SEQ ID NOs:1 and 2. Claim 56 expressly identifies the antibody as dupilumab. Claim 57 combines the antibody sequence, the product name, the adult patient population, prior intranasal corticosteroid treatment, add-on use and the 300 mg every-two-week regimen.

What is the patent's legal status and expiration date?

The patent was issued on August 28, 2018, and identifies Regeneron Pharmaceuticals, Inc. as the original assignee. Public patent records identify a February 15, 2012 priority date and a February 15, 2033 patent-term endpoint, subject to any applicable patent-term adjustment or terminal-disclaimer information recorded by the USPTO.[1]

Event	Date
Earliest reported priority date	February 15, 2012
US patent issue date	August 28, 2018
Patent number	US 10,059,771 B2
Nominal expiration date	February 15, 2033
Patent type	Method-of-use patent
Primary technology	Anti-IL-4R antibody treatment of nasal polyposis
Original assignee	Regeneron Pharmaceuticals, Inc.

The 2033 date is not the same as the full Dupixent exclusivity date. Dupilumab has separate composition, formulation, manufacturing and disease-specific patent families. The earliest enforceable barrier to a biosimilar may depend on which patents are asserted, whether the patents survive challenge and whether a settlement permits an earlier launch.

Patent expiration should therefore be analyzed as a portfolio question rather than by looking at US 10,059,771 alone.

What are the strongest claims in US Patent 10,059,771?

Claim 57 is the most commercially significant claim.

It requires:

An adult subject with nasal polyposis.
Disease inadequately controlled with intranasal corticosteroids.
Administration of dupilumab.
Add-on treatment.
A dose of 300 mg every two weeks.

This claim closely tracks the FDA-approved use of Dupixent for chronic rhinosinusitis with nasal polyposis in adults whose disease is inadequately controlled by intranasal corticosteroids.[2]

Claims 55 and 56 are also commercially important because they cover bilateral nasal polyposis and identify dupilumab expressly. Claims 23-38 protect repeated dosing, including 300 mg dosing and intervals from one to 15 weeks. Claim 50 adds patient-selection limitations based on bilateral nasal polyp score, biomarkers or eosinophilia.

Claims 1 and 23 are broader in disease and regimen terms but remain limited by the antibody sequence requirements. They do not cover every anti-IL-4R antibody or every treatment for nasal polyposis.

What technical and drafting issues affect claim scope?

The supplied text contains a material sequence-labeling inconsistency.

Claim 1 recites three light-chain CDR sequences from SEQ ID Nos: 6, 7 and 8 and then refers again to "three light chain" CDR sequences from SEQ ID Nos: 3, 4 and 5. In the surrounding claims, SEQ ID Nos:3, 4 and 5 are described as heavy-chain CDRs. Claim 23 uses the expected formulation: three light-chain CDRs from SEQ ID Nos:6, 7 and 8 and three heavy-chain CDRs from SEQ ID Nos:3, 4 and 5.

That discrepancy creates a potential claim-construction issue. A court would likely evaluate the claim in the context of the specification, prosecution history and dependent claims. The error could be treated as an obvious drafting mistake if the intrinsic record consistently identifies SEQ ID Nos:3-5 as heavy-chain CDRs. It could also provide an invalidity or indefiniteness argument if the claim language is read literally and the required antibody is internally undefined.

The issue is less important for claim 57, which identifies both the HCVR and LCVR sequences and names dupilumab. It remains relevant to claims 1-22 if those claims are asserted independently.

How broad are the dosing and administration claims?

The patent claims a wide range of doses and routes, but the commercially relevant regimen is narrower.

Claim	Dose or regimen	Assessment
Claim 4	0.1 mg to 600 mg	Broad numerical range
Claim 5	100 mg to 400 mg	Intermediate range
Claim 6	300 mg	Specific dose
Claim 10	Approximately 300 mg subcutaneously	Directly relevant to Dupixent
Claim 27	50 mg to 600 mg for initial and secondary doses	Broad repeated-dose range
Claim 29	300 mg for initial and secondary doses	Product-relevant
Claim 33	Secondary doses one to 15 weeks apart	Broad interval
Claims 34-36	Weekly, two-week or four-week dosing	Regimen-specific
Claim 57	300 mg every two weeks	Closest to the approved regimen

Claims 7-10 cover systemic, local, subcutaneous, intravenous and intranasal administration. Dupilumab is commercially administered subcutaneously. The intranasal and intravenous alternatives expand formal claim scope but have limited practical relevance unless a competing product uses one of those routes.

Claims 11-18 and 39-45 cover combination treatment with intranasal corticosteroids, inhaled corticosteroids, long-acting beta2 agonists, IgE inhibitors, antibiotics and antifungal agents. These claims may be difficult to enforce against ordinary clinical practice because the second therapy must be shown to be administered before, after or concurrently with dupilumab, and the relevant patient and antibody limitations must also be satisfied.

Does the patent cover the FDA-approved Dupixent nasal-polyps indication?

Yes. Claim 57 is closely aligned with the FDA-approved indication.

The FDA approved Dupixent for chronic rhinosinusitis with nasal polyposis in adults whose disease is inadequately controlled by intranasal corticosteroids. The approved dosing regimen is 300 mg by subcutaneous injection every other week.[2]

The patent uses the older or broader expression "nasal polyposis," while the FDA label uses "chronic rhinosinusitis with nasal polyposis." The terminology difference does not by itself eliminate overlap. In an infringement analysis, the key questions would include whether the treated patient has the claimed polyposis condition, whether intranasal corticosteroids inadequately controlled the disease and whether the administered product and regimen satisfy the sequence and dosing limitations.

The patent does not require every clinical endpoint in the FDA label. Claims 19, 20, 46 and 47 separately recite reductions in nasal polyp score or improvements in SNOT-22, nasal symptom score, NPIF, UPSIT and other parameters. Those limitations may strengthen an infringement theory where the outcome is documented, but they may also create proof burdens absent from the core treatment claims.

What is the Orange Book status of US Patent 10,059,771?

US Patent 10,059,771 is not an Orange Book patent in the conventional small-molecule sense.

Dupixent is a biologic licensed under the Public Health Service Act. Biologic patent information is associated with the Purple Book and the BPCIA patent-exchange process, not with an ANDA Paragraph IV certification in the FDA Orange Book.[3]

Consequences include:

A biosimilar applicant does not file an ANDA for dupilumab.
There is no conventional Paragraph IV certification against this patent.
The applicant may provide a BPCIA notice of commercial marketing.
Patent disputes may arise through the BPCIA patent-list exchange, declaratory judgment actions or infringement litigation under 35 U.S.C. §271(e)(2) in the biologics context.
FDA approval and patent clearance are separate questions.

The absence of an Orange Book listing does not eliminate the patent's enforceability. It changes the procedural route available to challengers.

Are there Paragraph IV challenges to this patent?

A conventional Paragraph IV challenge is not the expected pathway because Dupixent is a biologic, not a small-molecule drug approved under Section 505 of the Federal Food, Drug, and Cosmetic Act.

A future dupilumab biosimilar applicant would more likely challenge US 10,059,771 through one or more of the following:

A BPCIA patent-listing or patent-exchange dispute.
A declaratory judgment action.
An infringement action following commercial-marketing notice.
Invalidity defenses based on anticipation, obviousness, written description, enablement, indefiniteness or lack of patentable subject matter.
A non-infringement position based on a different indication, dosing regimen, patient population or antibody sequence.

The most vulnerable claims are likely to be those relying on broad dose ranges, broad administration routes or combinations that were predictable from the prior art. Claim 57 may be more difficult to avoid commercially because it maps closely to the approved nasal-polyposis regimen, but it remains exposed to validity challenges based on earlier clinical disclosures and obviousness arguments.

Which companies are challenging Dupixent exclusivity?

The principal competitive risk is from biosimilar developers rather than conventional generic manufacturers.

Potential biosimilar competitors include large biologics manufacturers and companies with established 351(k) capabilities. Publicly reported litigation and patent activity should be assessed patent-by-patent because a company may challenge composition, manufacturing, formulation or method-of-use patents in separate proceedings.

US 10,059,771 should not be treated as the sole or necessarily earliest barrier to a dupilumab biosimilar. The relevant competitor analysis must include:

Composition-of-matter patents covering dupilumab or anti-IL-4R antibodies.
Formulation and stability patents.
Cell-line, manufacturing and purification patents.
Treatment patents covering atopic dermatitis, asthma, eosinophilic esophagitis and chronic rhinosinusitis with nasal polyposis.
Pediatric and maintenance-regimen patents.
Settlement agreements and authorized or licensed biosimilar launch dates.

No conventional generic company can launch a dupilumab equivalent through the ANDA pathway.

How strong is the patent estate for nasal polyposis?

The estate is commercially strong but technically segmented.

Strengths

The patent has several enforcement advantages:

Claim 57 closely matches the approved product use.
The claims identify dupilumab through antibody sequences.
The patent covers the key 300 mg every-two-week regimen.
Claims cover bilateral disease and inadequate response to intranasal corticosteroids.
The claims include both treatment and patient-selection concepts.
The patent term extends into 2033 based on the reported priority and term data.

Vulnerabilities

The estate also has meaningful weaknesses:

Several claims are broad relative to the likely clinical evidence.
The claim set contains a sequence-labeling error in claim 1.
Biomarker claims may raise written-description and enablement issues if the specification does not support each marker and selection rule across the full scope.
Outcome claims can create proof problems because nasal polyp score, SNOT-22 and other measures may not be required for every patient.
Method-of-use claims do not prevent development of a biosimilar for a different indication if the sponsor can implement a lawful indication carve-out.
A biosimilar sponsor may contest infringement based on the prescribed use, label language and physician behavior.

The strongest litigation position would likely combine claim 57 with separate composition, formulation and manufacturing patents. US 10,059,771 alone is less likely to provide complete product-level protection against every biosimilar launch scenario.

What generic or biosimilar launch scenarios exist?

Scenario 1: Full-label biosimilar launch after patent expiry

A biosimilar sponsor seeks approval for the nasal-polyposis indication and launches after the relevant patents expire, are invalidated or are licensed.

Scenario 2: Carved-out indication

The sponsor removes nasal polyposis from its label while seeking approval for other dupilumab indications. This may reduce direct label-based infringement risk but does not eliminate potential induced-infringement allegations if the product is widely used for the patented indication.

Scenario 3: Settlement-based entry

Regeneron, Sanofi and a biosimilar sponsor agree to an entry date before the latest asserted patent expiration. The commercial date may depend on royalty terms, manufacturing rights and the scope of the release.

Scenario 4: Litigation-driven launch

The biosimilar sponsor launches at risk after challenging validity or infringement. The exposure would include damages, injunctive relief and potential product disruption.

Scenario 5: Non-infringing antibody or regimen

A competitor develops an antibody that does not meet the claimed CDR or variable-region limitations, or uses a materially different clinical regimen. This is technically difficult because dupilumab's established clinical profile creates strong commercial incentives to copy the validated mechanism and dosing schedule.

How does US 10,059,771 compare with other Dupixent patent protections?

Protection type	Function	Relevance to nasal polyposis
Composition patents	Protect antibody structure or sequence	Product-level protection across indications
Formulation patents	Protect concentration, excipients or stability	Manufacturing and product-substitution barrier
Manufacturing patents	Protect cell culture, purification or production methods	Difficult to design around if process is adopted
Method-of-use patents	Protect treatment of a defined disease	US 10,059,771's primary category
Dosing patents	Protect amount, frequency or loading regimen	Claims 23-38 and 57
Patient-selection patents	Protect biomarker or severity-defined populations	Claims 50-54

US 10,059,771 is strongest when combined with composition and manufacturing patents. Its value is narrower than a composition patent because a non-infringing biologic can avoid it, and a biosimilar sponsor may seek a label carve-out.

What licensing and settlement issues affect commercial value?

The supplied record does not identify a licensing agreement or settlement specific to US 10,059,771. The patent's commercial value would be affected by any agreement that:

Grants a biosimilar developer an earlier launch date.
Permits a licensed biosimilar under specified indications.
Releases only certain patents.
Preserves claims against an unapproved nasal-polyposis use.
Includes royalties, supply arrangements or manufacturing rights.
Resolves BPCIA litigation without invalidating the patent.

A settlement involving a separate Dupixent patent may still affect this patent's value if the agreement contains a portfolio-wide release or an agreed launch date.

Key Takeaways

US 10,059,771 is a method-of-use patent covering dupilumab treatment of nasal polyposis.
Claim 57 is the principal commercial claim because it tracks the approved 300 mg every-two-week add-on regimen for adults inadequately controlled by intranasal corticosteroids.
The reported patent expiration date is February 15, 2033.
The patent is not an Orange Book patent and is not subject to a conventional Paragraph IV challenge.
Future challenges would arise through the BPCIA and Purple Book framework.
The patent has strong label overlap but does not independently provide complete product-level protection.
Claim 1 contains a material heavy-chain/light-chain sequence-labeling inconsistency.
The strongest portfolio defense would combine this patent with composition, formulation, manufacturing and other Dupixent method-of-use patents.
Biosimilar launch risk depends on patent validity, label carving, BPCIA litigation and any portfolio settlement.

FAQs

Does US Patent 10,059,771 cover Dupixent itself?

It covers methods using an anti-IL-4R antibody with the specified sequences. Claims 55-57 identify dupilumab directly or through its variable-region sequences. It is not a general composition-of-matter claim covering dupilumab in every use.

Can a biosimilar applicant use a Paragraph IV certification against this patent?

No conventional Paragraph IV certification applies because Dupixent is a biologic. A biosimilar applicant would use the BPCIA framework and may challenge the patent through litigation or declaratory judgment proceedings.

Does the patent cover nasal polyps treated with dupilumab at 300 mg every four weeks?

Potentially, depending on the asserted claim. Claims 33 and 36 cover certain secondary-dose intervals, including four weeks, while claim 57 is limited to 300 mg every two weeks. Infringement would depend on all limitations of the specific claim asserted.

Are eosinophil levels required for every patient covered by the patent?

No. Claims 50-54 create a biomarker- and severity-selected subgroup. Other claims cover nasal polyposis without requiring elevated blood or sputum eosinophils.

Could a biosimilar avoid the patent by removing nasal polyposis from its label?

A label carve-out may reduce direct inducement and label-based infringement risk, but it does not automatically eliminate all infringement theories. Actual marketing, physician use, promotional conduct and the wording of the approved label would remain relevant.

References

United States Patent and Trademark Office. (2018). US Patent No. 10,059,771, Methods for treating nasal polyposis.
U.S. Food and Drug Administration. (2024). Dupixent (dupilumab) prescribing information. Regeneron Pharmaceuticals, Inc. and Sanofi.
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
Biologics Price Competition and Innovation Act, 42 U.S.C. § 262.
35 U.S.C. § 271(e)(2).

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Regeneron Pharmaceuticals, Inc.	DUPIXENT	dupilumab	Injection	761055	March 28, 2017	⤷ Start Trial	2034-06-20
Regeneron Pharmaceuticals, Inc.	DUPIXENT	dupilumab	Injection	761055	October 19, 2018	⤷ Start Trial	2034-06-20
Regeneron Pharmaceuticals, Inc.	DUPIXENT	dupilumab	Injection	761055	June 18, 2020	⤷ Start Trial	2034-06-20
Regeneron Pharmaceuticals, Inc.	DUPIXENT	dupilumab	Injection	761055	June 14, 2021	⤷ Start Trial	2034-06-20
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Patent: 10,059,771

Summary for Patent: 10,059,771